AUTHOR=King Lisa A. , Lameris Roeland , de Gruijl Tanja D. , van der Vliet Hans J. TITLE=CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond JOURNAL=Frontiers in Immunology VOLUME=9 YEAR=2018 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01519 DOI=10.3389/fimmu.2018.01519 ISSN=1664-3224 ABSTRACT=
CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response